Medications

EU fines pharma firms over generics delay (Update)

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives to a ...

Medications

India says its drugs safe after generics fraud

India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.

Medications

FDA: lower ambien's dose to prevent drowsy driving

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard while performing ...

Medications

Drug manufacturer agrees to $500 million penalty (Update)

A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown ...

Medications

FDA denies request to block generic painkiller

In a surprise move, federal health regulators have denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued can be more easily abused than its branded product.

Medications

FDA warns pregnant women about migraine drugs

(HealthDay)—Pregnant women who struggle with migraine headaches should never use medicines containing the ingredient valproate because they can lower the IQ scores of their children, the U.S. Food and Drug Administration ...

Medications

Fearing abuse, US blocks generic OxyContin (Update)

U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.

Medications

India's rejection of drug patent could reverberate

The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers.

Medications

India's top court to deliver Novartis judgment

India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they ...

page 6 from 10